Analysts expect Exact Sciences Corporation (NASDAQ:EXAS) to report ($0.31) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Six analysts have provided estimates for Exact Sciences Corporation’s earnings, with estimates ranging from ($0.34) to ($0.22). Exact Sciences Corporation posted earnings per share of ($0.36) in the same quarter last year, which indicates a positive year-over-year growth rate of 13.9%. The company is scheduled to report its next quarterly earnings report on Wednesday, October 25th.

According to Zacks, analysts expect that Exact Sciences Corporation will report full year earnings of ($1.19) per share for the current financial year, with EPS estimates ranging from ($1.28) to ($1.01). For the next fiscal year, analysts forecast that the business will post earnings of ($0.77) per share, with EPS estimates ranging from ($1.03) to ($0.49). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Exact Sciences Corporation.

Exact Sciences Corporation (NASDAQ:EXAS) last released its earnings results on Tuesday, July 25th. The medical research company reported ($0.27) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.37) by $0.10. The company had revenue of $57.65 million for the quarter, compared to analysts’ expectations of $47.73 million. Exact Sciences Corporation had a negative return on equity of 36.36% and a negative net margin of 83.08%.

Several equities research analysts recently commented on EXAS shares. Vetr cut Exact Sciences Corporation from a “strong-buy” rating to a “buy” rating and set a $36.13 price objective on the stock. in a research report on Wednesday, May 24th. Benchmark Co. increased their price objective on Exact Sciences Corporation from $34.00 to $50.00 and gave the company a “buy” rating in a research report on Wednesday, May 31st. Cowen and Company reaffirmed an “outperform” rating and set a $45.00 price objective on shares of Exact Sciences Corporation in a research report on Wednesday, May 31st. Canaccord Genuity increased their price objective on Exact Sciences Corporation from $38.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, May 31st. Finally, Jefferies Group LLC set a $35.00 price objective on Exact Sciences Corporation and gave the company a “buy” rating in a research report on Thursday, June 1st. Six investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $40.98.

In other Exact Sciences Corporation news, SVP D Scott Coward sold 1,987 shares of the firm’s stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $35.21, for a total value of $69,962.27. Following the transaction, the senior vice president now directly owns 57,603 shares of the company’s stock, valued at $2,028,201.63. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Jeffrey Thomas Elliott sold 5,846 shares of the firm’s stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $39.41, for a total value of $230,390.86. Following the completion of the transaction, the chief financial officer now directly owns 19,861 shares in the company, valued at $782,722.01. The disclosure for this sale can be found here. Insiders sold 129,291 shares of company stock worth $5,288,181 over the last three months. Insiders own 4.00% of the company’s stock.

A number of large investors have recently made changes to their positions in the business. Fortaleza Asset Management Inc. bought a new position in shares of Exact Sciences Corporation in the second quarter worth about $106,000. Krilogy Financial LLC raised its stake in shares of Exact Sciences Corporation by 1,460.0% in the second quarter. Krilogy Financial LLC now owns 3,900 shares of the medical research company’s stock worth $138,000 after buying an additional 3,650 shares during the period. Northwestern Mutual Wealth Management Co. raised its stake in shares of Exact Sciences Corporation by 17.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 4,072 shares of the medical research company’s stock worth $144,000 after buying an additional 600 shares during the period. Financial Architects Inc raised its stake in shares of Exact Sciences Corporation by 90.0% in the second quarter. Financial Architects Inc now owns 4,295 shares of the medical research company’s stock worth $152,000 after buying an additional 2,035 shares during the period. Finally, Johnson Financial Group Inc. raised its stake in shares of Exact Sciences Corporation by 25.9% in the second quarter. Johnson Financial Group Inc. now owns 4,862 shares of the medical research company’s stock worth $172,000 after buying an additional 1,000 shares during the period. 85.22% of the stock is currently owned by institutional investors and hedge funds.

Shares of Exact Sciences Corporation (EXAS) opened at 42.75 on Friday. The stock’s 50 day moving average price is $40.01 and its 200-day moving average price is $32.49. The company’s market capitalization is $5.09 billion. Exact Sciences Corporation has a 1-year low of $13.05 and a 1-year high of $43.50.

COPYRIGHT VIOLATION WARNING: This report was originally published by American Banking News and is the property of of American Banking News. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at https://www.americanbankingnews.com/2017/09/17/0-31-eps-expected-for-exact-sciences-corporation-exas-this-quarter.html.

Exact Sciences Corporation Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Get a free copy of the Zacks research report on Exact Sciences Corporation (EXAS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.